Interleukin-33 and Lower Tract Respiratory Diseases

Target Audience

This activity is designed to educate pulmonology, critical care medicine, infectious disease, and clinical immunology/allergy specialists who manage patients with severe viral lower respiratory tract disease, COPD, or other respiratory disorders. 

Program Overview

This live dinner symposium features expert panelists Dr. Jonathan M. Hand, Professor Dave Singh, and Professor Tom Wilkinson, who will explore the role of IL-33 in lower respiratory tract diseases and offer their insights on the latest advancements in treatment strategies that target its mechanisms. Agenda topics to be covered include the dual biologic function of IL-33 as both an inflammatory mediator and regulator of gene expression, IL-33 signaling pathways, implications of its dysregulation on the pathology of respiratory disease, rationale for targeting IL-33 for treatment development, and ongoing clinical investigations of biologic agents that inhibit IL-33. Interactive discussions and Q&A session will provide further opportunities for participant engagement and learning. 

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe IL-33 signaling and its pathophysiologic roles in COPD, severe viral lower respiratory tract disease, and other respiratory diseases
2. Discuss the mechanisms of action, clinical profiles, and published evidence for emerging biologic therapies targeting IL-33 for respiratory diseases
3. Incorporate emerging biologic therapies into practice for patients with COPD, severe viral lower respiratory tract disease, or other respiratory diseases as they become available

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan M. Hand, MD: Consulting Fees (e.g., advisory boards): AstraZeneca, Innoviva, Pfizer; Contracted Research: AstraZeneca, Ferring, Janssen, Pfizer, Scynexis

Professor Dave Singh, MD, FERS, FBPhS: Consulting fees (e.g. advisory boards): Adovate, Aerogen, Almirall, Apogee, Arrowhead, AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, Connect Biopharma, Covis, CSL Behring, DevPro Biopharma, Elpen, Empirico, EpiEndo, Genentech, Generate:Biomedicines, GSK, Glenmark, Kamada, Kinaset Therapeutics, Kymera, Menarini, MicroA, OM Pharma, Orion, Pieris Pharmaceuticals, Pulmatrix, Revolvo, Roivant Sciences, Sanofi, Synairgen, Tetherex, Teva, Theravance Biopharma, Upstream, Verona Pharma

Professor Tom Wilkinson, MA, Cantab, MBBS, PhD, FRCP, FERS: Consulting Fees (e.g., advisory boards): AstraZeneca, bioMérieux, Enanta, GSK, Janssen, Sanofi, Synairgen, TidalSense; Contracted Research: AstraZeneca, bioMérieux, GSK, Janssen, Sanofi, Synairgen;; Ownership Interest: Stock Options (or other ownership interest excluding diversified mutual funds): TidalSense

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.